Novel drug combinations suggested for treating pancreatic cancer
DOI:
https://doi.org/10.47577/biochemmed.v9i.11739Keywords:
Pancreatic cancer, gastrointestinal tumor, chemotherapeutic agents, advanced and metastatic disease, drug combinations, clinical trialsAbstract
Pancreatic cancer (PC) is a type of gastrointestinal tumor with poor anticipation and high level of death rate, being a fatal disease in which the overall 5-year survival rate is less than 4%1. PC poorly responds to most chemotherapeutic agents and the main current systemic chemotherapy treatments for patients with advanced disease are the drug combinations FOLFIRINOX and gemcitabine plus nanoparticle albumin-bound (nab)-paclitaxel (Abraxane). Therefore, there is a profound world-wide unmet medical need for new drug combination treatments having significant positive impact on the survival and day-to-day functioning of PC patients. It is suggested herein that treatment of drug combinations of bevacizumab plus bortezomib or dacarbazine and decitabine and optionally interferon α can be beneficial for patients suffering from locally advanced and metastatic PC, subject to creating predictive models to determine possible drug resistance and receiving positive results in clinical trials.
References
C. Pierantoni, A. Pagliacci, M. Scartozzi, R. Berardi, M. Bianconi and S. Cascinu, Pancreatic cancer: progress in cancer therapy, Critical Reviews in Oncology/Hematology, Volume 67, Issue 1, July 2008, Pages 27-38.
P. Raha, Outcome of combining epigenetic drugs with other treatments in the clinic, Medical Epigenetics (book), 799-826, 2016.
S. Feng and D. D. DeCarvalho, Clinical advances in targeting epigenetics for cancer therapy, The FEBS Journal, 289, 1214–1239, 2021.
J. Liu, P. Padya and S. Afshar, Therapeutic advances in oncology, Int. J. Mol. Sci. 22, 2008, 2021.
B. He, C. Lu, G. Zheng, X. He, M. Wang, G. Chen, G. Zhang and A. Lu, Combination therapeutics in complex diseases, J. Cell. Mol. Med. Vol 20, No 12, 2016, pp. 2231-2240.
C. Munck, H. K. Gumpert, A. I. Nilsson Wallin, H. H. Wang and M. O. A. Sommer, Prediction of resistance development against drug combinations by collateral responses to component drugs, Sci Transl Med. 2014; Vol 6, 262, pp 262ra156.
H.F Hu, Z. Ye, Y. Qin, X.W Xu, X.J Yu, Q.F Zhuo and S.Ji, Mutations in key driver genes of pancreatic cancer: Molecularly targeted therapies and other clinical implications, Acta Pharmacologica Sinica (2021) 42: 1725 – 1741.
Y. Xue , N. Barker , S. Hoon , P. He , T. Thakur, S. Raja Abdeen, P. Maruthappan , F. J Ghadessy and D. P Lane, Bortezomib stabilizes and activates p53 in proliferative compartments of both normal and tumor tissues in vivo, Cancer Res, 2019 Jul 15; 79 (14): 3595-36.
V. Heinemann, U. Vehling-Kaiser, D. Waldschmidt, E. Kettner A. Märten, C. Winkelmann, S. Klein, G. Kojouharoff, T. C. Gauler, L. Fischer von Weikersthal, M. R Clemens, M. Geissler, T.F. Greten, S. Hegewisch-Becker, O. Rubanov, G. Baake, T. Höhler, Y. D Ko, A. Jung, S. Neugebauer and S. Boeck, Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomized phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104), Gut. 2013; 62: 751–9.
R.K Ramanathan, A. Cnaan, R.G Hahn, P. P Carbone and D. G Haller, Phase II trial of dacarbazine in advanced pancreatic islet cell carcinoma, Ann Oncol. 2001 Aug;12(8):1139-43.
B. Eriksson, K. Oberg, G. Alm, A. Karlsson, G. Lundqvist, T. Andersson, E. Wilander, L. Wide, Treatment of malignant endocrine pancreatic tumors with human leucocyte interferon, Lancet 1986 Dec 6; 2(8519): 1307-9.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Meyer Elazar
This work is licensed under a Creative Commons Attribution 4.0 International License.
